Knowledge base

In-Vitro Dissolution: A Comprehensive Guide to Release Kinetics and f₂ Similarity Factor Analysis

In-vitro dissolution testing is a foundational tool in drug development, essential for assessing bioequivalence and ensuring consistent product quality following post-approval manufacturing changes (SUPAC). This technical guide details the mathematical principles of the f₂ similarity factor, essential regulatory compliance checklists, and the criteria for selecting optimal drug release kinetic models.

1. f₂ Similarity Factor: Fundamentals and Mathematical Basis

The similarity factor (f₂) is a model-independent mathematical approach used to measure the “sameness” or equivalence of two dissolution profiles. It represents a logarithmic reciprocal square root transformation of the sum of squared errors between the reference and test formulations:

f_{2} = 50 \times \log_{10} {{[1 + \frac{1}{n} \sum_{t = 1}^{n} {(R_{t} - T_{t})}^{2}]}^{- 0.5} \times 100}

Model-independent similarity factor (log typically base 10 per common regulatory practice). Variables n, R_t, and T_t are defined below.

Notation

n: Number of sampling time points.
R_t: Mean percent dissolved of the reference product at time t.
T_t: Mean percent dissolved of the test product at time t.

Technical Interpretation and Acceptance Limits

Similarity criterion

An f₂ value between 50 and 100 indicates that the two dissolution profiles are similar.

Interpretation when f₂ equals 50

An f₂ value of exactly 50 corresponds to an average absolute difference of 10% across all time points.

Variability constraints

To ensure the reliability of mean data, the coefficient of variation (CV) must not exceed 20% at the earliest time point (for example 15 minutes) and 10% at subsequent time points.

When multivariate approaches are required

When the within-batch variation exceeds these limits, the standard f₂ calculation is considered unsuitable. In such cases, the Mahalanobis distance-based multivariate model-independent confidence-region procedure applies.

2. FDA and EMA f₂ Compliance Checklist

Regulatory agencies maintain strict boundary conditions for f₂ calculations to ensure data integrity. Note the critical difference in the plateau rule between agencies:

Requirement	Regulatory Specification
Minimum time points	At least 3 points, excluding zero.
Identical timing	Time points must be exactly matching for test and reference batches.
≥85% rule (FDA)	Include only one measurement after both products reach 85% dissolution.
≥85% rule (EMA)	Include only one measurement after either product reaches 85% dissolution (typically evaluated when the reference does).
Sample size	12 individual dosage units for both formulations.
Biowaiver / exemption	f₂ calculation is not required if both products reach >85% dissolution within 15 minutes.

3. Release Kinetics: Model Selection and Evaluation

Beyond determining similarity, researchers fit dissolution data to mathematical models to identify the underlying drug transport mechanism.

Standard kinetic models

Zero-order kinetics: Constant drug release rate over time, often used when describing prolonged-action systems such as osmotic pumps.
First-order kinetics: Release rate proportional to remaining drug mass; frequently observed with porous matrix systems.
Higuchi model: Describes release as a diffusion-controlled process consistent with Fick’s law, with extent scaling with the square root of time.
Korsmeyer–Peppas model: Semi-empirical power law where the exponent n informs the prevailing release mechanism.

Decision-support metrics

Model selection benefits from contrasting several objective measures rather than maximizing a single fit statistic alone:

Adjusted R²: Penalizes superfluous parameters relative to ordinary R², improving comparability across models.
Akaike information criterion (AIC): Lower values indicate preferable trade-offs between explanatory power and complexity.
Bayesian information criterion (BIC): Applies a stronger complexity penalty than AIC for parsimonious selection when datasets are sizable.

References

Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123-133.
Diaz, D. A., et al. (2016). Dissolution Similarity Requirements: Global Regulatory Expectations. The AAPS Journal, 18(1), 15-22.
EMA (2010). Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1.
EMA (2014). Guideline on quality of oral modified release products. EMA/CHMP/QWP/428693/2013.
FDA (1997). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms.
FDA (1997). SUPAC-MR: Modified Release Solid Oral Dosage Forms.
FDA (2018). Dissolution Testing for IR Products Containing High Solubility Drug Substances.
Xie, F., et al. (2015). In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria. European Journal of Pharmaceutical Sciences, 66, 163-172.